Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter and Conference Paper
Incidence and Severity of Amphotericin B-induced Acute Toxicity in Leukemic Patients After Treatment with Three Different Formulations (Amphotericin B, AmBisome and Amphotericin B/lntralipid) — A Pilot Study
Intravenous amphotericin B (AmB) is the most potent drug for treatment of systemic fungal infections in leukemic patients. However, use of this drug is often limited by renal side effects and acute toxicity (f...